Zomedica (ZOM) Price, Hedge Fund Trends, Analyst Price Targets, News & more

Zomedica
ZOM

Delisted

ZOM was delisted on the 5th of March, 2025.

Back to rankings

About: Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its operations are comprised of two reportable segments namely Diagnostic and Therapeutic Devices. It earns the majority of revenue from the therapeutics segment.

Employees: 144

Financial journalist opinion

Zomedica Corp. Announces Transition to OTCQB Venture Market

Zomedica's ticker symbol will change to ZOMDF ANN ARBOR, MI / ACCESS Newswire / March 4, 2025 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a leading veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced that its common shares will be delisted from the NYSE American exchange, due to their determination that the Company is no longer suitable for listing pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low selling price of the common shares. Zomedica has made arrangements with the OTCQB Venture Market for its shares to begin trading on the OTCQB Venture Market exchange under the ticker symbol "ZOMDF", effective March 5, 2025.

NYSE American to Commence Delisting Proceedings Against Zomedica Corp. (ZOM)

NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common shares of Zomedica Corp. (the “Company”) — ticker symbol ZOM — from NYSE American. Trading in the Company's common shares will be suspended immediately. NYSE Regulation has determined that the Company is no longer suitable for listing pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to.

Zomedica to Report Fourth Quarter and Full Year 2024 Financial Results with a Business Update on March 13th at 4:30 p.m. ET

ANN ARBOR, MI / ACCESS Newswire / February 26, 2025 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, will host a conference call and audio-only webcast on Thursday, March 13, 2025, at 4:30 p.m. ET to discuss the Company's operational and financial highlights for its fourth quarter and full year ended December 31, 2024.

Zomedica Improves Efficiency and Cuts Costs by Moving to New Headquarters

Relocation to More Efficient Space Supports Growth While Reducing Overhead by Over $200,000 Annually ANN ARBOR, MI / ACCESS Newswire / February 12, 2025 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that that Company has relocated its corporate headquarters to a new facility in Ann Arbor, Michigan. "Our new headquarters marks an exciting milestone for Zomedica.

Zomedica Launches the TRUFORMA(R) Enhanced Endogenous ACTH Assay to aid in Equine PPID Diagnosis

Zomedica continues to redefine what is possible in point of care diagnostics with the TRUFORMA biosensor platform ANN ARBOR, MI / ACCESS Newswire / February 6, 2025 / Zomedica Corp. (NYSE American:ZOM), a veterinary health company offering point-of-care diagnostics and therapeutic devices for equine and companion animals, today announced a groundbreaking update to its endogenous ACTH (eACTH) assay for equine plasma on the TRUFORMA biosensor platform. Since it was launched in September of 2024, the TRUFORMA eACTH assay has been widely adopted as the only assay to measure eACTH in horses directly at the point-of-care.

Zomedica Announces License & Supply Agreement with Cresilon Inc. to Market and Sell Vetigel(R) Hemostatic Gel in the Animal Health Market

License Agreement Expands Zomedica's Portfolio with Revolutionary Hemostatic Technology ANN ARBOR, MI / ACCESSWIRE / January 7, 2025 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that it had entered into a license and supply agreement with Cresilon, Inc. to market and sell the Vetigel® hemostatic gel product line on an exclusive basis in the United States and on a non-exclusive basis outside the United States. Under the terms of the agreement, Zomedica will assume responsibility for supplying U.S. customers and will collaborate with Cresilon to support customers outside the U.S. This partnership enables Zomedica to further its mission of delivering innovative solutions that enhance patient care and operational efficiency for veterinary practitioners.

Zomedica Launches Two New Quantitative Assays on the TRUFORMA(R) Platform: Canine NT-proBNP and Progesterone

With the addition of these two new assay launches, Zomedica has added 8 new assays in the past 18 months to the rapidly growing TRUFORMA Platform ANN ARBOR, MI / ACCESSWIRE / December 23, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the launch of two new canine assays for the TRUFORMA In-Clinic Biosensor Testing Platform. Zomedica's canine NT-poBNP test is used for the quantitative detection of NT-proBNP in canine EDTA plasma or serum.

Zomedica Appoints Scott A. Jordan Executive Vice President, Finance & Chief Financial Officer

Seasoned executive brings a broad skill set to Zomedica's leadership team ANN ARBOR, MI / ACCESSWIRE / December 19, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, announced that it has appointed Scott A. Jordan as its Executive Vice President, Finance and Chief Financial Officer, effective January 1, 2025.

Zomedica to Present at the NobleCon20 Twentieth Annual Emerging Growth Equity Conference December 4, 2024

ANN ARBOR, MI / ACCESSWIRE / November 27, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that its Chief Executive Officer, Larry Heaton, will present and host one-on-one meetings with investors at NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, Florida on Wednesday, December 4, 2025 at 11:00 am Eastern Standard Time. A high-definition video webcast of the presentation will be available the following day on the Company's website, www.zomedica.com, and as part of a complete catalog of presentations available at Noble Capital Markets' Conference website, www.nobleconference.com, and on the investor portal created by Noble, Channelchek at www.channelchek.com.

Zomedica Launches Quantitative Insulin Assay for Equine Plasma on the TRUFORMA(R) Platform

Combined with Zomedica's eACTH assay, equine veterinarians get same day answers for their PPID and EMS patients ANN ARBOR, MI / ACCESSWIRE / November 14, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the launch of its third equine-focused assay - Insulin for equine plasma - for the TRUFORMA In-Clinic Biosensor Testing Platform. Veterinarians test equine insulin levels when they suspect Equine Metabolic Syndrome (EMS) or other forms of insulin dysregulation, as frequently occurs with equine Cushing's disease, or Pituitary Pars Intermedia Dysfunction (PPID), with prevalence reported between 18-27% of ponies and horses.

See News Rankings

Charts implemented using Lightweight Charts™